Your browser doesn't support javascript.
A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection.
Taylor, Sean C; Hurst, Beth; Charlton, Carmen L; Bailey, Ashley; Kanji, Jamil N; McCarthy, Mary K; Morrison, Thomas E; Huey, Leah; Annen, Kyle; DomBourian, Melkon G; Knight, Vijaya.
  • Taylor SC; GenScript USA Inc., Piscataway, New Jersey, USA sean.taylor@genscript.com.
  • Hurst B; Cayman Chemical, Ann Arbor, Michigan, USA.
  • Charlton CL; Public Health Laboratory, Alberta Precision Laboratories (ProvLab), University of Alberta Hospital, Edmonton, AB, Canada.
  • Bailey A; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
  • Kanji JN; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada.
  • McCarthy MK; Public Health Laboratory, Alberta Precision Laboratories (ProvLab), University of Alberta Hospital, Edmonton, AB, Canada.
  • Morrison TE; Public Health Laboratory, Alberta Precision Laboratories (ProvLab), University of Alberta Hospital, Edmonton, AB, Canada.
  • Huey L; Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
  • Annen K; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • DomBourian MG; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Knight V; Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
J Clin Microbiol ; 59(4)2021 03 19.
Article in English | MEDLINE | ID: covidwho-1177521
ABSTRACT
Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody function as neutralizing, correlating with protection from reinfection. A new assay technology measuring the interaction of the purified SARS-CoV-2 spike protein receptor binding domain (RBD) with the extracellular domain of the human angiotensin-converting enzyme 2 (hACE2) receptor detects these important antibodies. The cPass surrogate virus neutralization test (sVNT), compared directly with eight SARS-CoV-2 IgG serology and two live-cell neutralization tests, gives similar or improved accuracy for qualitative delineation between positive and negative individuals in a fast, scalable, and high-throughput assay. The combined data support the cPass sVNT as a tool for highly accurate SARS-CoV-2 immunity surveillance of infected/recovered and/or vaccinated individuals as well as drug and convalescent-phase donor screening. The data also preview a novel application for the cPass sVNT in calibrating the stringency of live-cell neutralization tests and its use in longitudinal testing of recovered and/or vaccinated patients.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Diagnostic study / Prognostic study / Qualitative research Topics: Vaccines Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: JCM.02438-20

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Diagnostic study / Prognostic study / Qualitative research Topics: Vaccines Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: JCM.02438-20